The problem of @entity209 is one of the most important in medicine today. The main hazard of @entity209 is development of @entity32 in adipose tissue, which promotes @entity731 , @entity1561 , @entity2401 , and a number of other illnesses. Therefore, understanding of molecular mechanisms of @entity32 in adipose tissue is very important for treatment of @entity209 . Three main components that arise during @entity1184 and @entity1373 of adipocytes underlie such @entity32 : endoplasmic reticulum stress, oxidative stress, and @entity519 . Each of these components mediates activation in different ways of the key factor of @entity32 - NF-kB. For @entity209 therapy, it is suggested to influence a number of inflammatory signaling components by activating other cell factors to suppress development of @entity32 . Such potential factors are peroxisome proliferator-activated receptors type y that suppress transcription factor NF-kB through direct contact or via kinase of a NF-kB inhibitor (IKK), and also the antiinflammatory transcription factor @entity1178 . Other possible targets are type 3 @entity2125 -dependent histone deacetylases (sirtuins). There are mutually antagonistic relationships between NF-kB and @entity4093 that prevent development of @entity32 in @entity209 . Moreover, @entity4093 inhibits the antiinflammatory transcription factor @entity1178 . Study of the influence of these factors on the relationship between macrophages and adipocytes, macrophages, and adipose tissue-derived stromal cells can help to understand mechanisms of signaling and development of @entity32 in @entity209 .

Molecular Mechanisms of Latent Inflammation in XXXX . Possible Role of Sirtuins and Peroxisome Proliferator-Activated Receptor Type y.

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'latent inflammation'] @entity2125 :: ('MESH:D009243', 'Chemical') :: ['NAD+'] @entity4093 :: ('23411', 'Gene') :: ['sirtuin type 1'] @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia'] @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxia'] @entity1561 :: ('MESH:D065626', 'Disease') :: ['non-alcoholic fatty liver disease'] @entity1178 :: ('3725', 'Gene') :: ['AP-1'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis'] @entity2401 :: ('MESH:D009205', 'Disease') :: ['myocarditis']
@entity209 :: (MESH:D008659,Disease) :: ['Metabolic Syndrome']
